Still the short treatment interval and the life-threating condition counterbalance this risk and seem to rectify the inclusion of sorafenib to the cytoreductive if FLT3-ITD-positive AML with hyperleukocytosis. Here, FLT3 is linked to acute myeloid leukemia.